NextCell Pharma completes a directed share issue to a strategic partner
The Board of Directors of NextCell Pharma AB (”NextCell or the ”Company”) has today, based on the authorization granted by the Annual General Meeting held on 24 November 2020, resolved on a directed issue of 286 666 new shares (the “Share Issue”) to Polski Bank Komórek Macierzystych S.A (”PBKM”), Europes largest stem cell bank and an important partner to the Company. The subscription price in the share isse amounts to SEK 15 per new share, giving the Company approximately SEK 4,3 million in issue proceeds.
The Board of Directors of NextCell has today, based on the authorization granted by the Annual General Meeting held on 24 November 2020, resolved on the Share Issue. The Share Issue comprises 286,666 new shares at a subscription price of SEK 15 per new share, which means that the Company will receive approximately SEK 4.3 million in issue proceeds. The subscription price of SEK 15 has been determined by the Company's Board of Directors after negotiations with PBKM and corresponds to a discount of approximately 9.4 per cent in relation to the volume-weighted average price of the Company's shares during the past ten (10) trading days. It is the Board of Directors’ assessment that the subscription price accurately reflects current market conditions and demand.
The main purpose of the Share Issue is to provide the Company with the strategically important investor PBKM, which is Europe's largest stem cell bank and an important partner of the Company. This is also the reason for the deviation from the shareholders' preferential rights.
Through the Share Issue, the number of outstanding shares and votes in the Company will increase by 286,666 from 33,426,191 to 33,712,857. The share capital will increase by SEK 58,766.53 from SEK 6,852,369.155 to SEK 6,911,135.685. The Share Issue entails a dilution for existing shareholders of approximately 0.85 percent of the number of shares and votes in the Company.
This information is such information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 21 January 2021, 21:35 CET.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
Website:
www.nextcellpharma.com, www.cellaviva.se
www.cellaviva.dk
About NextCell Pharma AB
NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.
FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.